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Abstract 
Background: 
Cumulative anticholinergic exposure (anticholinergic burden) has been linked to a 
number of adverse outcomes. To conduct research in this area an agreed 
approach to describing anticholinergic burden is needed.  
Objective: 
This review set out to identify anticholinergic burden scales, to describe their 
rationale, the settings in which they have been used and the outcomes associated 
with them. 
Methods: 
A search was performed using the Healthcare Databases Advanced Search 
(HDAS) of Medline, Embase, Cochrane, CINAHL and PsycINFO from inception to 
October 2016 to identify systematic reviews describing anticholinergic burden 
scales or tools. Abstracts and titles were reviewed to determine eligibility for 
review with eligible articles read in full. The final selection of reviews was critically 
appraised using the ROBIS tool and pre-defined data were extracted; the primary 
data of interest were the anticholinergic burden scales or tools used.  
Results: 
Five reviews were identified for analysis containing a total of 62 original articles. 
18 anticholinergic burden scales or tools were identified with variation in their 
derivation, content and how they quantified the anticholinergic activity of 
medications. The Drug Burden Index was the most commonly used scale or tool 
in community and database studies, while the Anticholinergic Risk Scale was used 
more frequently in care homes and hospital settings. Association between 
anticholinergic burden and clinical outcomes varied by index and study. Falls and 
hospitalisation were consistently found to associate with anticholinergic burden. 
Mortality, delirium, physical function and cognition were not consistently 
associated.  
Conclusions: 
Anticholinergic burden scales vary in their rationale, use and association with 
outcomes. This review showed that the concept of anticholinergic burden has 
been variably defined and inconsistently described using a number of indices with 
different content and scoring. The association between adverse outcomes and 
anticholinergic burden varies between scores and has not been conclusively 
established. 
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Key points 
 
• There are multiple available methods to quantify anticholinergic burden 
• The available methods vary in their derivation and association with 
outcomes.  
• An agreed method of quantifying anticholinergic burden is needed to aid 
future potential research in this field.
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1.Introduction 
 
1.1 Rationale 
 
Medications with anticholinergic properties are widely used for a variety of 
indications. Such products may not be used primarily for their anticholinergic 
effect and may not be routinely identified as having anticholinergic activity by 
practicing clinicians[1]. However, the cumulative effect of multiple medications 
with  anticholinergic effects, known as anticholinergic burden, is potentially 
significant and is an area of specific concern in the research literature[2]. 
Anticholinergic burden scales are designed to quantify the cumulative exposure to 
anticholinergic activity[3]. A number of scales have been developed and have 
been used in a number of clinical settings including inpatients[4], community 
dwellers[5] and institutional care[6]. They are referred to by a number of terms, 
but for simplicity throughout the article ‘anticholinergic burden scale’ will be used.  
 
Older people, with a higher rate of multimorbidity and subsequent polypharmacy, 
are at higher risk of experiencing anticholinergic burden compared to younger 
people and with age-related changes to pharmacokinetics and pharmacodynamics 
are at higher risk of anticholinergic side effects for a given anticholinergic 
burden[7]. This applies all the more in the frailest groups such as care home 
residents and people with dementia, where the risk of multimorbidity and 
polypharmacy is high[8].  
 
Previous reviews have identified that all anticholinergic burden scales in use show 
an association between anticholinergic burden and at least one adverse 
outcome[2] and researchers have therefore called for interventions to reduce 
anticholinergic burden[9]. Clearly, a starting point for such interventions is a clear 
and consistent understanding of how to quantify and measure anticholinergic 
burden. Preliminary reading of the published reviews, however, showed variation 
in the type and number of scales/tools identified with Salahudeen and colleagues 
identifying seven[1] and Mayer and colleagues identifying 12[10]. In addition 
there was variation in the authors’ views on the appropriateness of the different 
scales/tools with Cardwell and colleagues advocating the use of the Drug Burden 
Index[2] while Salahudeen and colleagues identified the Anticholinergic Cognitive 
Burden Scale as the most frequently validated scale[1]. In order to help clarify 
this divergence of view a review of reviews was proposed to comprehensively 
identify anticholinergic burden scales and tools.   
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1.2 Objectives 
The primary objective of this systematic review of reviews was: 
(i) To identify scales / tools that have been used to quantify 
anticholinergic burden. 
The secondary objectives of this review were: 
(i) To describe the rationale of the identified scales 
(ii) To describe the settings in which the identified scales have been used. 
(iii) To describe any associations between anticholinergic burden, as 
quantified by the identified anticholinergic burden scales, and adverse 
outcomes. 
  
2. Methods 
 
2.1 Eligibility and exclusion criteria 
Systematic reviews describing the use of scales or tools to quantify 
anticholinergic burden were deemed eligible. For the purposes of this review 
articles that stated that they were planned and reported in accordance with the 
preferred reporting items for systematic reviews and meta-analyses 
(PRISMA)[11] were deemed to be systematic. No publication date or age of 
participant restrictions were imposed but the search was limited to reviews and 
English language articles. Reviews marked as narrative or clinical were excluded 
as were reviews that sought to test the association between prespecified 
anticholinergic burden scales and outcomes.  
 
2.2 Information sources and study selection 
An electronic literature search was performed using Healthcare Databases 
Advanced Search (HDAS) of Medline, Embase, Cochrane, CINAHL and PsycINFO 
from inception to October 2016 for relevant articles. The last full search was run 
on the 24th of October 2016.  
 
2.3 Search 
The following terms, a mixture of MeSH and free text, were used:  
Anticholinergics OR cholinergic receptor blocking agents OR cholinergic antagonist 
OR antimuscarinics OR muscarinic receptor blocking agents OR muscarinic 
antagonist AND risk OR risk measure OR risk scale OR rating scale OR risk tool 
OR load OR drug burden index. An example search (Medline) is given in Electronic 
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Supplementary Material Appendix S1. The reference lists of included reviews were 
searched for additional relevant studies (snowballing).  
 
2.4 Study selection 
The titles and abstracts of the identified articles were screened to see whether 
they met the inclusion criteria. Where there was uncertainty, full length articles 
were evaluated before a final decision on inclusion was made. A list of excluded 
studies is included in Electronic Supplementary Material Table S1. 
 
2.5 Data collection 
Full text copies of included articles were reviewed and data were extracted and 
entered into a structured Microsoft Excel (Redmond, WA, USA) database. For 
each article, the following variables were populated: (i) the anticholinergic burden 
scales used (ii) information on the scales’ rationale (iii) the number of participants 
evaluated using the different scales (iv) the use of the scales in different settings 
(hospital, community, care home (including nursing homes, long-term care 
facilities and homes for the aged), database studies and in people with dementia) 
(v) (where available) adverse events associated with anticholinergic burden as 
defined by different anticholinergic burden scales  
 
2.6 Assessment of risk of bias 
The ROBIS tool was used to assess the risk of bias for each systematic 
review[12]. The ROBIS tool is a method to assess bias in systematic reviews 
which is completed in three phases (1) assessing relevance, (2) identifying 
concerns with the review process and (3) judging risk of bias in the review. Phase 
two involves assessing the review across four domains: (i) study eligibility 
criteria, (ii) identification and selection of studies, (iii) data collection and study 
appraisal and (iv) synthesis and findings. In phase three the findings of phase 
two and signalling questions are used to evaluate the overall risk of bias. Table 1 
summarises the risk of bias for each review.  
 
 
3 Results 
4656 articles were identified by the search. After limiting the search to review 
articles in English 906 citations remained. The abstracts of these remaining 
articles were screened and 14 full text papers were identified and subsequently 
reviewed for inclusion. From this group a final total of 5 were included after 
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detailed review revealed that 9 articles did not meet the inclusion criteria (Figure 
1). 
 
 
 
Figure 1 Preferred reporting items for systematic reviews and meta-analyses 
(PRISMA) literature search and study selection flow chart[11]  
 
 
Table 1 ROBIS[12] assessment of risk of bias in included reviews 
Review Phase 2 Any concerns 
identified? 
Phase 3 
(i) 
Study 
eligibility 
criteria 
(ii) 
Identification 
and selection 
of studies 
(iii) 
Data 
collection 
and study 
appraisal 
(iv) 
Synthesis 
and 
findings 
Risk of 
bias 
Cardwell 
et al.[2] 
(2015) 
Low Low Low Low No additional search 
over and above the 
electronic search was 
conducted. However 6 
databases were 
searched, reducing the 
risk of missed studies. 
Low 
Duran et 
al.[3] 
(2013) 
Low Low Low Low No formal risk of bias 
assessment was 
carried out. 
Low 
Mayer et 
al.[10] 
(2015) 
Low Low Low Low Only one database 
used for the electronic 
search and no formal 
risk of bias 
assessment was made. 
However these issues 
were appraised during 
the authors’ 
discussion. 
Low 
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Salahudee
n et al. 
[1] 
(2015) 
Low Low Low Low No Low 
Villalba-
Moreno et 
al. [7] 
2016 
Low Low Low Low No formal risk of bias 
assessment carried 
out. 
Low 
 
 
 
3.1 Characteristics of included reviews 
Four of the review articles set out to identify anticholinergic burden scales and to 
test their association with clinical outcomes[1, 2, 7, 10]. Two produced an 
anticholinergic burden scale by combining pre-existing scales[1, 3], and one set 
out to identify the most useful scale for longitudinal research[2].  
The five reviews cited a combined total of 62 original research articles. They  
included variable numbers of primary studies: Cardwell[2] 13 studies, Duran[3] 7 
studies, Mayer[10] 55 studies, Salahudeen[1] 38 studies and Villalba-Moreno[7] 
25 studies. All reported on association with adverse outcomes. The characteristics 
of the cited studies are summarised in table 2. 60 of the articles reported on 
observational studies, while the remaining two reported on randomised controlled 
trials. Of the 60 observational studies 30 were cross-sectional and 30 longitudinal 
(including 4 database studies using primary care data). 699,792 people were 
studied in the 62 articles. 22,555 people were recruited from the community, 
6172 from hospital (inpatients), 4253 from outpatients and 5316 from care 
homes or equivalents. Database studies reported data from 661,496 participants 
across a variety of settings. The findings of each study are summarised in table 2.  
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Table 2 Characteristics and findings of included studies 
Scale Study Study design Population Dementia N Age 
(years)a 
Duration 
(years)  
Adverse outcome(s) 
studied 
Association? 
Present (+) 
Absent (-)  
Aizenberg’s 
Anticholinergic 
burden scale  
 
Aizenberg et 
al. 2002[13] 
Prospective Hospital No 414 >65 4 Falls + 
Anticholinergic 
Activity Scale  
 
Ehrt et al. 
2010[14] 
Longitudinal 
cohort 
Community (PD) No 78 74.7 8 Cognitive function  + 
Anticholinergic 
Burden 
Classification  
 
Ancelin et 
al. 2006[5] 
Longitudinal 
study 
Nursing home No  372 >60 U Cognitive function + 
Anticholinergic 
Cognitive 
Burden scale  
 
Kolanowski 
et al. 
2009[15] 
Cross sectional Nursing home Yes 87 >66 2.17 Quality of life - 
Campbell et 
al. 2010[16] 
Longitudinal Community No  1652 >70 6 Cognitive function + 
Campbell et 
al. 2011[17] 
Observational 
cohort 
Hospital No  147 >65 U Delirium  - 
Fox et al. 
2011[18] 
Longitudinal 
cohort 
Nursing, 
residential, day 
hospital, 
inpatients 
Yes – 
(Alzheimer’s 
disease) 
224 81 +/-
7.4 
1.5 Cognitive function - 
Fox et al. 
2011[19] 
Longitudinal 
cohort 
Community 
dwelling and 
institutional 
No  1304 >65 2 Cognitive function + 
Mortality + 
Cai et al 
2013[20] 
Retrospective 
cohort 
Primary care 
clinic 
No  3690 >65 1 Cognitive function + 
Koyama et Prospective  Community No  1429 >75 5 Function  + 
 10 
Anticholinergic drug burden tools/scales and adverse outcomes  
a. 2014[21] (women) Cognition - 
Koyama et 
al 2013[22] 
Longitudinal Community 
(women) 
No  1484 >75 10 Cognitive function + 
Dementia + 
Pasina et al 
2013[23] 
Cross sectional 
prospective  
Hospital No  1380 >65 0.25 Cognitive function + 
Physical function + 
Shah et al. 
2013[24] 
Cohort study Community 
(catholic clergy) 
No 896 >65 10 Cognitive function + 
Kidd et al. 
2014[25] 
Retrospective  Hospital No  419 >90 0.25 Mortality - 
Length of stay - 
Kashyap et 
al. 2014[26] 
Longitudinal 
cohort 
Outpatient No  102 71.9 +/- 
7.3 
1 Cognitive function + 
Mangoni et 
al. 2013[27] 
Cross-
sectional 
Hospital No  71 84 +/-6 1 Mortality - 
Lanctot et 
al. 2014[28] 
Cross-
sectional 
Outpatients with 
coronary artery 
disease 
No  U 64.2 ± 
9.1 
NA  Attention, speed, 
executive function 
+ 
Anticholinergic 
Loading scale  
 
Sittironnarit 
et al. 
2011[29] 
Cross-
sectional 
 Community Yes -
Alzheimer’s 
disease  
133 78 +/-
8.6 
1.83 Psychomotor speed 
and executive function 
+ 
Anticholinergic 
Drug Scale  
 
Carnahan et 
al. 2002[6] 
Cross-
sectional 
Nursing home No  U U NA  SAA + 
Carnahan et 
al 2006[30] 
Cross-
sectional 
Long-term care 
residents 
No  279 86 0.08 SAA + 
Kersten et 
al. 2013[31] 
RCT Nursing home No  64 85 0.92 Cognitive function - 
Kersten et 
al. 2013[32] 
Cross-
sectional 
Nursing home No  87 73 1 Cognitive function - 
Function - 
Lampela et 
al. 2013[33] 
Cross-
sectional 
Community No  621 >75 3 Adverse events + 
Cognitive function + 
Function  + 
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Low et al. 
2009[34] 
Longitudinal Community No  2058 60-64 4 Cognitive function + 
Kashyap et 
al. 2014[26] 
Longitudinal 
cohort 
Outpatient No  102 71.9 +/- 
7.3 
1 Cognitive function + 
Juliebø et al. 
2009[35] 
Prospective Hospital (with hip 
fracture) 
No  364 >65 0.01 Delirium - 
Drag et al. 
2012[36] 
Cross-
sectional 
Hospital No  450 67.9 +/- 
10.5 
0.08 Cognitive function - 
Mangoni et 
al. 2013[27] 
Cross-
sectional 
Hospital No  71 84 +/-6 1 Mortality - 
Kalisch et 
al. 2014[37] 
Retrospective Community 
(Australian 
veterans) 
No  36015 80 2 Risk of hospitalisation 
for delirium or 
dementia 
+ 
Anticholinergic 
Risk Scale  
 
Rudolph et 
al. 2008[38] 
Retrospective 
and 
prospective 
cohort 
Hospital No  132 >65 0.75 Central adverse effect 
(confusion, dizziness, 
falls) 
+ 
Rudolph et 
al. 2008[38] 
Retrospective 
and 
prospective 
cohort 
Long-term care No  117 >65 0.83 Central adverse effect 
(confusion, dizziness, 
falls) 
+ 
Kumpula et 
al. 2011[39] 
Prospective 
cohort 
Hospital and 
Long-term care 
No  1004 81.3 1 Mortality - 
Lowry et al. 
2011[40] 
Prospective 
cohort 
Hospital No  362 83.6 +/-
6.6 
0.42 Activities of daily 
living  
- 
Mortality - 
Length of stay + 
Lowry et al. 
2011[41] 
Cohort study Hospital No  362 83.6 +/-
6.6 
0.42 Institutionalisation 
and comorbidities 
+ 
Koshoedo et 
al. 2012[42] 
Cohort study Rehab unit No  117 79 +/-7 0.75 Activities of daily 
living  
+ 
Lampela et Cross- Community No  621 >75 3 Adverse events + 
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al. 2013[33] sectional Cognitive function + 
Function  + 
Landi et al. 
2014[43] 
Cohort study Nursing homes No  1490 >65 1 Functional decline + 
Falls + 
Delirium + 
Pasina et al. 
2013[23] 
Cross sectional 
prospective  
Hospital No  1380 >65 0.25 Cognitive function + 
Physical function + 
Kashyap et 
al. 2014[26] 
Longitudinal 
cohort 
Outpatient No  102 71.9 +/- 
7.3 
1 Cognitive function + 
Mangoni et 
al. 2013[27] 
Cross-
sectional 
Hospital No  71 84 +/-6 1 Mortality - 
Huang et al. 
2012[44] 
Retrospective National Health 
Insurance 
database 
No  54888 >65 1.5 Emergency visit + 
Hospitalisation + 
Constipation + 
Delirium + 
Cardiac arrhythmia + 
Cognitive impairment - 
Kalisch et 
al. 2014[37] 
Retrospective Community 
(Australian 
veterans) 
No  36015 80 2 Risk of hospitalisation 
for delirium or 
dementia 
+ 
Bostock et 
al. 2013[45] 
Prospective 
observational 
Hospital No  271 U U Activities of daily 
living  
+ 
Cognitive function  - 
Dispennette 
et al. 
2014[46] 
Retrospective Vulnerable 
patients 
No  229 >65 NA Risk of readmission + 
Teramura-
Gronblad et 
al. 2011[47] 
Cross-
sectional 
Nursing homes No  1475 81.7 +/- 
7.6 
NA Psychological well-
being 
+ 
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Zimmerman 
et al. 
2014[4] 
Cross-
sectional 
Inpatients 
(Palliative) 
No  217 72.9 +/- 
12.8 
NA Delirium + 
Walter et al. 
2014[48] 
Retrospective Outpatients No  125 ? NA Failed post-operative 
void trial 
+ 
Cancelli’s 
Anticholinergic 
Burden scale  
 
Cancelli et 
al. 2008[49] 
Retrospective Dementia centre 
(outpatients) 
Yes – 
Alzheimer’s 
disease 
230 77 +/- 6 NA Psychosis + 
Cancelli et 
al. 2008[50] 
Cross-
sectional 
Community No  750 >65 NA Cognitive impairment + 
Chew’s list Lampela et 
al. 2013[33] 
Cross-
sectional 
Community No  621 >75 3 Cognitive function + 
Function  + 
Chew 
2008[51] 
Cross-
sectional 
in vitro No  107 NA NA Anticholinergic activity 
in vitro 
 
Jessen et al. 
2010[52] 
Cohort Community No  2605 >75 4.5 Dementia risk + 
Clinician-rated 
Anticholinergic 
Score  
 
Han et al. 
2008[53] 
Prospective 
cohort 
Community No  544 >65 2 Cognitive function + 
Function + 
Agar et al. 
2009[54] 
RCT Palliative care No  461 71 0.17 Quality of life + 
Functional outcome + 
Yeh et al. 
2013[55] 
Prospective 
cohort 
Veteran dementia 
care home 
Dementia 53 83.4 0.23 Cognitive function - 
Han et al. 
2001[56] 
Longitudinal 
observational 
study 
Hospital No  278 83.4 +/- 
7.3 
0.06 Delirium symptom - 
Dementia diagnosis - 
Drug Burden 
Index  
 
Best et al. 
2013[57] 
Cross-
sectional 
Hospital No  329 >65 NA Delirium + 
Gnjidic et al 
2009[58] 
Cross-
sectional 
Community No  1705 76.9 +/- 
5.5 
NA Physical function + 
Gnjidic et al 
Feb 
2012[59] 
Cross-
sectional 
Self-care 
retirement homes 
No  115 >70 NA Physical function + 
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Gnjidic et al 
April 
2012[60] 
Cross-
sectional 
Community No  887 >70 NA Cognitive function - 
Gnjidic et al 
Aug 
2012[61] 
Cross-
sectional 
Community No  700 >75 NA Physical function + 
Gnjidic et al 
2014[62] 
Retrospective 
cohort 
Community / 
database 
Yes - 16603 
with 
Alzheimer’s 
disease 
33206 >65 U Mortality + 
Hospitalisation + 
Wilson et al 
2012, 2011, 
2010[63-
65]  
Retrospective  Nursing home   
No  
602  >70   
NA 
Mortality - 
Falls + 
Balance and walking 
speed 
- 
Bostock et 
al. 2013[45]  
Prospective 
observational  
Hospital  No 271  U U Activities of daily 
living 
+ 
Cognitive function - 
Cao et al. 
2008[66] 
 
Cross-
sectional 
Community No  932 >65 NA Physical performance + 
Hilmer et al. 
2007[67] 
Cross-
sectional 
 
Community 
 
No  3075 
 
>70 
 
NA Physical status + 
Cognitive function + 
Dispennette 
et al. 
2014[46] 
Retrospective Vulnerable 
patients 
No  229 >65 NA Risk of readmission + 
Mangoni et 
al. 2013[27] 
Cross-
sectional 
Hospital No  71 84 +/-6 1 Mortality - 
Lowry et al 
2012[68] 
Prospective 
cohort 
Hospital No  362 83.6 +/-
6.6 
0.42 Activities of daily 
living 
- 
Mortality - 
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Length of stay + 
Lönnroos et 
al. 2012[69] 
Prospective 
observational 
cohort 
Community No  339 81.0 +/- 
6.6 
1 Hospitalisation + 
Dauphinot 
et al. 
2014[70] 
 
Longitudinal 
observational 
cohort 
 
Hospital 
 
No 337 
 
85.4 +/- 
6.6 
 
0.97 
 
Mortality - 
Falls + 
Nishtala et 
al. 2014[71] 
Cross-
sectional 
Community / 
database 
No  537387 >65 NA Falls related 
hospitalisation 
+ 
GP visits + 
Mortality + 
Bosboom et 
al 2012[72] 
Cross-
sectional 
Care homes Yes 351 >65 NA Quality of life + 
Drug Burden 
Index – World 
Health 
Organisation  
 
Dauphinot 
et al. 
2014[70] 
Longitudinal 
observational 
cohort 
Hospital 
 
 
No  
337 
 
85.4 +/- 
6.6 
0.97 Mortality - 
Minzenberg – 
Clinical Index 
and 
Pharmacological 
Index  
 
Minzenberg 
et al. 
2004[73] 
Cross-
sectional 
 
Outpatients with 
schizophrenia 
 
 
No  
106 
 
39.9 +/- 
11.3 
 
NA Simple attention - 
Complex attention + 
Short-term memory + 
Delayed recall + 
Semantic memory + 
Working memory - 
Executive functions - 
Factor scores 
(declarative memory) 
+ 
Summers’ Drug 
risk number  
Han et al. 
2001[56] 
 
Longitudinal 
observational 
study 
 
Hospital 
 
 
No  
278 
 
83.4 +/- 
7.3 
 
0.06 
 
Delirium symptom - 
Dementia diagnosis - 
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Whalley’s 
Anticholinergic 
Burden scale  
 
Whalley et 
al. 2012[74] 
Longitudinal 
observational 
study 
Community No  281 77-78 10 Cognitive impairment + 
Developing dementia - 
Data are mean ± SD unless stated otherwise 
 
Key: NA= Not applicable, SAA= serum anticholinergic activity, U= Unknown or data unavailable. 
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3.2 Synthesis of reviews 
3.2.1 Anticholinergic burden scales 
 
Eighteen different anticholinergic burden scales were identified between the five 
reviews. No single review identified all 18 anticholinergic burden scales. Nine 
were developed by teams in the USA[30, 38, 51, 53, 67, 73, 75, 76], eight were 
produced by teams based in the UK[74], Israel[13], Norway[14], France[5], 
Italy[50], Ecuador[3] and New Zealand[1] while one scale aimed to be 
international in outlook[70].  
 
The evidence used to develop the scales varied between in vitro receptor binding 
testing to expert opinion and is summarised in table 3. 
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Table 3. Characteristics of and rationale behind the identified anticholinergic burden scales 
 
Scale Study Country Scoring 
range 
Scoring criteria 
  Receptor 
bonding / serum 
anticholinergic 
activity 
Laboratory 
data 
Anticholinergic 
effect 
Expert 
opinion 
Systematic 
review +  
synthesis 
Aizenberg’s 
Anticholinergic 
Burden scale  
 
Aizenberg et al. 
2002[13] 
Israel 
0-5   X   
Anticholinergic 
Activity Scale  
 
Ehrt et al.  
2010[14] 
Norway  
0-4 X   X  
Anticholinergic 
Burden Classification  
 
Ancelin et al. 
2006[5] 
France  
0-3 X   X  
Anticholinergic 
Cognitive Burden 
Boustani et al. 
2008[75] 
USA  
0-3 X  X X  
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scale  
 
Anticholinergic 
Loading scale  
 
Sittironnarit et 
al. 
2011[29] 
Australia  
0-3 X   X  
Anticholinergic Drug 
Scale  
 
Carnahan et al. 
2006[30] 
USA  
0-3   X   
Anticholinergic risk 
scale  
 
Rudolph et al. 
2008[38] 
USA  
0-3   X X  
Cancelli’s  
Anticholinergic 
Burden scale  
 
Cancelli et al. 
2008[50] 
Italy 
0-3   X X  
Chew’s list 
Chew et al. 
2008[51] 
USA 
0-4 X     
Clinician-rated 
Anticholinergic Score  
 
Han et al. 
2008[53] 
USA  
0-3  X X X  
Drug Burden Index 
(Anticholinergic 
component)* 
 
Hilmer et al. 
2007[67] 
USA 
0-1      
Drug Burden Index – 
World Health 
Organisation*  
Dauphinot et al. 
2014[70] 
Internatio
nal 
0-1      
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Duran’s  
Anticholinergic 
Burden scale  
 
Duran et al. 
2013[3] 
Ecuador 
0-3     X 
Minzenberg – Clinical 
Index and 
Pharmacological 
Index  
 
Minzenberg et 
al. 2004[73] 
USA 
1-228   X X  
Minzenberg – Clinical 
Index and 
Pharmacological 
Index  
 
Minzenberg et 
al. 2004[73] 
USA 
0.7-1470 X     
Salahudeen’s 
Anticholinergic 
Burden scale  
 
Salahudeen et 
al. 
2015[1] 
New 
Zealand 
High, 
moderate, 
low 
X    X 
Summers’ Drug risk 
number  
Summers et al. 
1978[76] 
USA 
0-3 X     
Whalley’s 
Anticholinergic 
Burden scale  
 
Whalley et al.  
2012[74] 
UK 
0-3 X   X  
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* The Drug Burden Index is calculated using prescribed and recommended doses of medications. The medications composing the 
Anticholinergic component of the scale were identified using Mosby's Drug Consult[77] and the Physicians' Desk Reference[78].
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3.2.2 Agreement between scales 
Salahudeen and colleagues compared the drugs included in the Anticholinergic 
Drug Scale, Anticholinergic Burden Classification, Clinician rated Anticholinergic 
Score, Anticholinergic Risk Scale, Anticholinergic Cognitive Burden scale, 
Anticholinergic Activity Scale and Anticholinergic Loading Scale[1]. Out of 195 
medications 34 (17%) were scored differently in different scales and 12 (6%) 
were scored as having low anticholinergic effect in at least one scale but having 
high anticholinergic activity in another. 
 
 
3.2.3 Population sizes 
The Drug Burden Index was used to quantify the anticholinergic burden in the 
largest number of participants, followed by the Anticholinergic Risk Scale, 
Anticholinergic Drug Scale and Anticholinergic Cognitive Burden scale while the 
Anticholinergic Activity Scale was applied in the smallest population. Electronic 
Supplementary table S2summarises the numbers of participants assessed using 
the different scales. 
 
3.2.4 Population settings 
The reviews identified studies which were conducted in a number of different 
settings; with some conducted in multiple settings. These included the 
community[8, 14, 16, 18-22, 24, 29, 33, 34, 37, 52, 53, 58, 66, 67, 69, 74, 79] 
(21), hospital[4, 13, 17, 23, 25, 27, 35-41, 45, 46, 56, 57, 68, 70] (19), 
outpatients[18, 26, 28, 48, 49, 73] (6), care homes (or equivalents)[5, 6, 15, 18, 
19, 30-32, 38, 39, 42, 43, 47, 55, 59, 63-65, 72] (19) and databases[37, 44, 62, 
71] (4). 
 
The Drug Burden Index was the most commonly used scale in the community and 
in database studies, while the Anticholinergic Risk Scale dominated in care homes 
and hospital settings. Electronic Supplementary table S3 summarises the 
numbers of participants assessed using the different scales. 
 
3.2.5 Dementia 
 
Eight out of the 62 studies involved populations where all participants had 
dementia. The Drug Burden Index was the most commonly used scale followed by 
the Anticholinergic Cognitive Burden scale. Table 4 shows further breakdown. 
 
Table 4. Anticholinergic burden scales used in people with dementia  
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Scale Total 
populations 
with 
dementia 
studied 
Setting(s) Association 
with outcome 
events 
No 
association 
with 
outcome 
events 
Anticholinergic 
Cognitive 
Burden scale  
 
1207 Care 
homes,  
inpatients 
Cognitive 
function 
Quality of life, 
Cognitive 
function 
Anticholinergic 
Loading scale  
 
133 Community Psychomotor 
speed and 
executive 
function 
 
Cancelli’s 
Anticholinergic 
Burden scale  
 
230 Outpatients Psychosis  
Clinician-rated 
Anticholinergic 
Score  
 
53 Veteran 
home 
 Cognitive 
function 
Drug Burden 
Index  
 
351 
(16603) 
Care 
homes, 
(database) 
Mortality, 
hospitalisation, 
quality of life. 
 
 
 
3.2.6 Association with adverse outcomes 
Of the studies reporting outcomes related to falls and hospitalisation, all reported 
an association with anticholinergic burden. Of the studies reporting mortality, 
delirium and physical function outcomes the majority found an association with 
anticholinergic burden. Of the studies reporting on cognitive function the majority 
showed no association with anticholinergic burden. Table 5 shows further details. 
 
Table 5. Association between anticholinergic burden and outcomes 
Outcome Scale(s) Stud
ies 
N studies, 
involving N 
participants 
(association) 
N studies, 
involving N 
participants  
(no 
association) 
Falls Aizenberg’s Anticholinergic 
Burden scale  
Anticholinergic Risk Scale  
Drug Burden Index  
 
7 
 
 
 
7,  
540479 
0, 
0 
Hospitalisation  8 8, 
698308 
0, 
0 
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Anticholinergic Drug Scale  
Anticholinergic Risk Scale  
Drug Burden Index  
Mortality Anticholinergic Cognitive 
Burden scale  
Anticholinergic Drug Scale  
Anticholinergic Risk Scale  
Drug Burden Index – World 
Health Organisation  
Drug Burden Index  
9 3, 
571897 
6, 
2193 
Delirium Anticholinergic Cognitive 
Burden scale  
Anticholinergic Drug Scale  
Anticholinergic Risk Scale  
Cancelli’s  Anticholinergic 
Burden scale  
Clinician-rated 
Anticholinergic Score 
Summers’ Drug Risk 
Number   
Drug Burden Index  
8 5, 
57154 
3, 
789 
Cognitive 
function 
Anticholinergic Activity 
Scale  
Anticholinergic Burden 
Classification  
Anticholinergic Cognitive 
Burden scale  
Anticholinergic Drug Scale  
Anticholinergic Risk Scale  
Cancelli’s Anticholinergic 
Burden scale  
Clinician-rated 
Anticholinergic Score  
Drug Burden Index  
Whalley’s  Anticholinergic 
Burden scale 
24 16, 
17666 
8, 
58082 
Physical 
function  
Anticholinergic Cognitive 
Burden scale   
Anticholinergic Drug Scale  
Anticholinergic Risk Scale  
Chew’s list 
Clinician-rated 
16 12, 
12840 
4, 
1051 
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Anticholinergic Score  
Drug Burden Index  
 
 
 
4 Discussion 
This review of reviews has demonstrated that multiple different scales have been 
developed to quantify anticholinergic burden. These have been developed 
variously based on expert opinion, clinical anticholinergic effects and in vitro 
testing. They have been applied to outpatients, inpatients, community dwellers, 
care home residents and in database studies. The Drug Burden Index was the 
most frequently used scale / tool as reported by these studies. More studies 
reported an association between increasing anticholinergic burden and falls, 
hospitalisation, mortality and physical function than those that did not. Although 
more studies reported an association with cognitive function than those that did 
not, the studies reporting no association involved more participants.  
 
This review identified studies using 18 different anticholinergic burden scales, 
more than any of the individual reviews [1-3, 7, 10], suggesting that this 
approach has been more comprehensive. The individual studies identified as part 
of this review occurred in a number of different settings and included a number of 
large scale database/population studies. Findings drawn from these data are 
therefore likely to be applicable in a number of different settings.   
 
The chief limitation of the approach taken in this review is the potential for bias 
introduced by including only previous reviews, rather than seeking out newer 
empirical studies published in the interim. Some potentially pertinent studies may 
have been missed by this method and since the completion of the review we have 
become aware of one such example [80].  However, this potential has been 
mitigated to a degree by the number of reviews included and their recent 
publication dates. In addition the primary focus of this review was to identify 
existent scales rather than to assess the association between anticholinergic 
burden and outcomes. We have chosen to present data on association with 
outcomes where it has been reported in the included reviews. However, reviews 
whose principal aim was to examine this association were not included and this 
does potentially introduce bias. This is mitigated to a degree by the large number 
of included studies. Finally, the use of only a single reviewer was not ideal and 
this may have increased the risk of missing relevant studies. However, the fact 
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that this review identified more anticholinergic burden scales than any of the 
individual reviews suggests this is unlikely to have been a significant problem.  
 
Anticholinergic burden in older people has been studied extensively [1, 3], 
however the variation in anticholinergic burden scales used, the metrics used to 
assess outcomes and the outcomes themselves make it challenging to synthesise 
the data. The reviews all concluded that there is a lack of a universal approach to 
assessing anticholinergic burden, which handicaps interpretation of any findings. 
The different scales include different drugs and attribute markedly different 
anticholinergic activity to the same drugs[3]. Salahudeen and colleagues[1] and 
Duran[3] and colleagues both propose new scales derived from synthesis of the 
existing scales but at the time of this review of reviews these had not been 
tested.  
 
A larger population had been assessed using the Drug Burden Index than any 
other anticholinergic burden scale due to its use in database studies and it has 
been shown to be associated with a number of outcomes of interest[71]. 
However, the approach is more time consuming than other anticholinergic burden 
scales and copyright restrictions on the use of the “Drug Burden Index 
Calculator”, which limits its use to registered Australian healthcare 
practitioners[81], inevitably curbs its potential widespread application. 
Discounting the Drug Burden Index, the Anticholinergic Risk Scale was the most 
frequently used scale in care home and inpatient studies, while the Anticholinergic 
Cognitive Burden scale was the most frequently used in community dwellers and 
in people with dementia. Both the Anticholinergic Risk Scale and Anticholinergic 
Cognitive Burden scale were associated with outcomes of interest, although 
within the studies examining people with dementia association between 
anticholinergic burden and outcomes was variable and inconsistent. The lack of a 
clear association between anticholinergic burden and cognitive outcomes was 
surprising and is an area that warrants closer investigation. 
 
5 Conclusion 
There are at least 18 anticholinergic burden scales. These scales vary in their 
derivation, content and rating of the anticholinergic activity of the same 
medications. Although the Drug Burden Index has been most extensively used, 
there are practical considerations which limit its implementation. Of the remaining 
scales the Anticholinergic Risk Scale and Anticholinergic Cognitive Burden scale 
have the most experience in rating anticholinergic burden in care home residents 
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and people with dementia respectively. The Anticholinergic Risk Scale shows 
association with relevant clinical outcomes while the data for the Anticholinergic 
Cognitive Burden scale in people with dementia are mixed.  
 
Although the approach has been hampered by methodological issues this review 
has suggested that the evidence of association between anticholinergic burden 
and adverse outcomes is not as clear cut as some authors have suggested. Two 
avenues of enquiry will need to be pursued to help clarify the association between 
anticholinergic burden and outcomes. Firstly, formal systematic review of the use 
of anticholinergic burden scales as reported in original research articles with 
particular focus placed on the quality of the evidence is needed. Secondly, 
additional empirical research testing the use of the most evidence-based scales in 
their appropriate clinical context is needed to better understand whether the 
differences in classification and weighting of anticholinergic effects in different 
scales are justified. By combining these two approaches greater clarity on the 
association between anticholinergic burden, as reported by anticholinergic burden 
scales, and outcomes will be achieved. 
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